Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Krystal Biotech reported robust Q2 2025 results, with VYJUVEK net revenue reaching $96 million, totaling over $525 million since launch, and achieving $1.29 diluted EPS, marking two consecutive years of profitability. While Q3 U.S. revenue is expected to dip due to seasonal patient pauses, a strong Q4 rebound is anticipated from ongoing sales force expansion and patient restarts, with over 575 U.S. reimbursement approvals secured. Crucially, the company is set for significant global expansion, launching VYJUVEK in Europe this quarter (Germany, France) and Japan before year-end. Furthermore, Krystal advanced its pipeline with positive KB304 aesthetic data, initiated repeat dosing for KB408 in AATD, and commenced two new ophthalmology trials, signaling a broad portfolio with multiple near-term clinical readouts.

Analysis

Krystal Biotech reported a strong second quarter for 2025, demonstrating continued commercial execution and financial discipline. Net revenue for VYJUVEK reached $96 million, a 9% sequential increase, bringing total revenue since launch to over $525 million. The company has maintained profitability for two consecutive years, posting a diluted EPS of $1.29 for the quarter. While management guided for a temporary dip in Q3 U.S. revenue due to seasonal patient pausing, a return to growth is expected in Q4, driven by an expanding sales force and patient restarts. The U.S. foundation remains solid with over 575 reimbursement approvals and 82% compliance among patients on therapy, although this rate is expected to moderate as the patient mix shifts to milder cases. The key forward-looking catalysts are the imminent global launches of VYJUVEK in Germany and France this quarter, followed by Japan before year-end, which are expected to significantly augment the revenue trajectory. Concurrently, the pipeline is advancing with promising updates, including a 36% objective response rate for inhaled KB707 in NSCLC, the start of a repeat-dosing cohort for KB408 in AATD, and the initiation of two new ophthalmology trials, underscoring the platform's broad potential beyond its initial indication.

Key Decisions for Investors

• Investors should anticipate the guided short-term revenue volatility in Q3 for U.S. VYJUVEK sales but monitor for a rebound in Q4 as the full impact of the expanded sales force is realized.
• The primary focus should be on the initial commercial uptake and pricing outcomes from the European and Japanese launches, as successful execution in these markets is critical to validating the drug's path to blockbuster status.
• Upcoming clinical readouts, particularly for KB408 in AATD and KB707 in oncology, present significant long-term value catalysts and should be watched closely as they could de-risk the platform and expand the company's addressable markets.
• Consider the potential value creation from the planned spin-out of the Jeune aesthetics subsidiary by late 2026, which could unlock a distinct investment opportunity and sharpen Krystal's focus on its core therapeutic areas.